Abstract
Purpose
Glioma is a highly malignant and unfavorable cancer in the brain. Recent evidence highlights the vital role of cilia-related pathways as novel regulators of glioma development. However, the prognostic potential of ciliary pathways in glioma is still ambiguous. In this study, we aim to construct a gene signature using cilia-related genes to facilitate the prognostication of glioma.
Methods
A multi-stage approach was employed to build the ciliary gene signature for prognostication of glioma. The strategy involved the implementation of univariate, LASSO, and stepwise multivariate Cox regression analyses based on TCGA cohort, followed by independent validation in CGGA and REMBRANDT cohort. The study further revealed molecular differences at the genomic, transcriptomic, and proteomic levels between distinct groups.
Results
A prognostic tool utilizing a 9-gene signature based on ciliary pathways was developed to assess the clinical outcomes of glioma patients. The risk scores generated by the signature demonstrated a negative correlation with patient survival rates. The validation of the signature in an independent cohort reinforced its prognostic capabilities. In-depth analysis uncovered distinctive molecular characteristics at the genomic, transcriptomic, and protein-interactive levels in the high- and low-risk groups. Furthermore, the gene signature was able to predict the sensitivity of glioma patients to conventional chemotherapeutic drugs.
Conclusion
This study has established the utility of a ciliary gene signature as a reliable prognostic predictor of glioma patient survival. Findings not only enhance our comprehension of the intricate molecular mechanisms of cilia pathways in glioma, but also hold significant clinical implications in directing chemotherapeutic strategies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Availability of data and materials
The gene expression profiles utilized in this study are publicly accessible on TCGA (https://portal.gdc.cancer.gov/) and CGGA (http://www.cgga.org.cn/). The analytic protocols are available from the corresponding author upon reasonable request.
Abbreviations
- GBM:
-
Glioblastoma
- GO:
-
Gene ontology
- ROC:
-
Receiver-operating characteristic
- AUC:
-
Area under the curve
- TCGA:
-
The Cancer Genome Atlas
- CGGA:
-
The Chinese Glioma Genome Atlas
- OS:
-
Overall survival
- PPI:
-
Protein–protein interaction
References
Alvarez-Satta M, Matheu A (2018) Primary cilium and glioblastoma. Ther Adv Med Oncol 10:1758835918801169. https://doi.org/10.1177/1758835918801169
Basten SG, Giles RH (2013) Functional aspects of primary cilia in signaling, cell cycle and tumorigenesis. Cilia 2(1):1–23
Beck AH, Knoblauch NW, Hefti MM, Kaplan J, Schnitt SJ, Culhane AC, Schroeder MS, Risch T, Quackenbush J, Haibe-Kains B (2013) Significance analysis of prognostic signatures. PLoS Comput Biol 9(1):e1002875. https://doi.org/10.1371/journal.pcbi.1002875
Breslow DK, Holland AJ (2019) Mechanism and regulation of centriole and cilium biogenesis. Annu Rev Biochem 88:691–724
Cao M, Zou X, Li C, Lin Z, Wang N, Zou Z, Ye Y, Seemann J, Levine B, Tang Z (2023) An actin filament branching surveillance system regulates cell cycle progression, cytokinesis and primary ciliogenesis. Nat Commun 14(1):1687
Deleyrolle LP, Sarkisian MR (2023) Cilia at the crossroads of tumor treating fields and chemotherapy. Dev Neurosci 45:139–146
Deleyrolle L, Harrison J, Takacs G, Sarkisian M (2022) TMIC-32 tumor cell cilia associate with specific immune cell populations in human and mouse models of GBM. Neurooncology 24(7):vii278
Dolly SO, Wagner AJ, Bendell JC, Kindler HL, Krug LM, Seiwert TY, Zauderer MG, Lolkema MP, Apt D, Yeh RF, Fredrickson JO, Spoerke JM, Koeppen H, Ware JA, Lauchle JO, Burris HA 3rd, de Bono JS (2016) Phase I study of apitolisib (GDC-0980), dual phosphatidylinositol-3-kinase and mammalian target of rapamycin kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 22(12):2874–2884. https://doi.org/10.1158/1078-0432.CCR-15-2225
Fliegauf M, Benzing T, Omran H (2007) When cilia go bad: cilia defects and ciliopathies. Nat Rev Mol Cell Biol 8(11):880–893
Goranci-Buzhala G (2020) Characterization of primary cilia in patient-derived glioma stem cells. Universität zu Köln, Cologne
Gusev Y, Bhuvaneshwar K, Song L, Zenklusen JC, Fine H, Madhavan S (2018) The REMBRANDT study, a large collection of genomic data from brain cancer patients. Sci Data 5:180158. https://doi.org/10.1038/sdata.2018.158
Han S, Liu Y, Cai SJ, Qian M, Ding J, Larion M, Gilbert MR, Yang C (2020) IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. Br J Cancer 122(11):1580–1589
Kaushal P, Zhu J, Wan Z, Chen H, Ye J, Luo C (2023) Prognosis and immune landscapes in glioblastoma based on gene-signature related to reactive-oxygen-species. Neuromol Med 25(1):102–119
Kim S, Dynlacht BD (2013) Assembling a primary cilium. Curr Opin Cell Biol 25(4):506–511
Li T, Yang W, Li M, Zhang S, Zhou X, Zuo M, Yuan Q, Chen M, Liu Y (2020) Engrailed 2 (EN2) acts as a glioma suppressor by inhibiting tumor proliferation/invasion and enhancing sensitivity to temozolomide. Cancer Cell Int 20:65. https://doi.org/10.1186/s12935-020-1145-y
Li L, Leng W, Chen J, Li S, Lei B, Zhang H, Zhao H (2023) Identification of a copper metabolism-related gene signature for predicting prognosis and immune response in glioma. Cancer Med 12(8):10123–10137
Liang X, Wang Z, Dai Z, Zhang H, Zhang J, Luo P, Liu Z, Liu Z, Yang K, Cheng Q (2023) Glioblastoma glycolytic signature predicts unfavorable prognosis, immunological heterogeneity, and ENO1 promotes microglia M2 polarization and cancer cell malignancy. Cancer Gene Ther 30(3):481–496
Liu X, Liu P, Chernock RD, Kuhs KAL, Lewis JS Jr, Luo J, Gay HA, Thorstad WL, Wang X (2020) A prognostic gene expression signature for oropharyngeal squamous cell carcinoma. EBioMedicine 61:102805. https://doi.org/10.1016/j.ebiom.2020.102805
Lu J, Huang X-Y, Wang Y-H, Xie J-W, Wang J-B, Lin J-X, Chen Q-Y, Cao L-L, Li P, Huang C-M (2020) POC1A acts as a promising prognostic biomarker associated with high tumor immune cell infiltration in gastric cancer. Aging (albany NY) 12(19):18982
Ludwig K, Kornblum HI (2017) Molecular markers in glioma. J Neurooncol 134:505–512
Marenco-Hillembrand L, Wijesekera O, Suarez-Meade P, Mampre D, Jackson C, Peterson J, Trifiletti D, Hammack J, Ortiz K, Lesser E (2020) Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis. J Neurooncol 147:297–307
Molinaro AM, Taylor JW, Wiencke JK, Wrensch MR (2019) Genetic and molecular epidemiology of adult diffuse glioma. Nat Rev Neurol 15(7):405–417
Moser JJ, Fritzler MJ, Rattner JB (2014) Ultrastructural characterization of primary cilia in pathologically characterized human glioblastoma multiforme (GBM) tumors. BMC Clin Pathol 14:40. https://doi.org/10.1186/1472-6890-14-40
Omeljaniuk WJ, Kretowski R, Ratajczak-Wrona W, Jablonska E, Cechowska-Pasko M (2021) Novel dual PI3K/mTOR inhibitor, apitolisib (GDC-0980), inhibits growth and induces apoptosis in human glioblastoma cells. Int J Mol Sci. https://doi.org/10.3390/ijms222111511
Park K, Leroux MR (2022) Composition, organization and mechanisms of the transition zone, a gate for the cilium. EMBO Rep 23(12):e55420
Reinhardt LS, Moras AM, Henn JG, Arantes PR, Ferro MB, Braganhol E, de Souza PO, de Oliveira Merib J, Borges GR, Dalanhol CS, de Barros Dias MCH, Nugent M, Moura DJ (2022) Nek1-inhibitor and temozolomide-loaded microfibers as a co-therapy strategy for glioblastoma treatment. Int J Pharm 617:121584. https://doi.org/10.1016/j.ijpharm.2022.121584
Sarkisian MR, Semple-Rowland SL (2019) Emerging roles of primary cilia in glioma. Front Cell Neurosci 13:55. https://doi.org/10.3389/fncel.2019.00055
Sarkisian MR, Siebzehnrubl D, Hoang-Minh L, Deleyrolle L, Silver DJ, Siebzehnrubl FA, Guadiana SM, Srivinasan G, Semple-Rowland S, Harrison JK, Steindler DA, Reynolds BA (2014) Detection of primary cilia in human glioblastoma. J Neurooncol 117(1):15–24. https://doi.org/10.1007/s11060-013-1340-y
Shi P, Tian J, Mallinger J, Deleyrolle L, McIntyre J, Caspary T, Breunig J, Sarkisian MR (2022) Increasing ciliary ARL13B expression drives active and inhibitor-resistant SMO and GLI into glioma primary Cilia. bioRxiv. 2028:518234
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for, R., Treatment of Cancer Brain, T., Radiotherapy, G., & National Cancer Institute of Canada Clinical Trials, G (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. https://doi.org/10.1056/NEJMoa043330
Tan AC, Ashley DM, Lopez GY, Malinzak M, Friedman HS, Khasraw M (2020) Management of glioblastoma: State of the art and future directions. CA Cancer J Clin 70(4):299–312. https://doi.org/10.3322/caac.21613
Venoux M, Tait X, Hames RS, Straatman KR, Woodland HR, Fry AM (2013) Poc1A and Poc1B act together in human cells to ensure centriole integrity. J Cell Sci 126(Pt 1):163–175. https://doi.org/10.1242/jcs.111203
Wang L, Wen X, Wang Z, Lin Z, Li C, Zhou H, Yu H, Li Y, Cheng Y, Chen Y (2022) Ciliary transition zone proteins coordinate ciliary protein composition and ectosome shedding. Nat Commun 13(1):3997
Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister SM, Nishikawa R, Rosenthal M, Wen PY, Stupp R (2015) Glioma. Nat Rev Dis Prim 1(1):1–18
Yabo YA, Niclou SP, Golebiewska A (2022) Cancer cell heterogeneity and plasticity: a paradigm shift in glioblastoma. Neuro Oncol 24(5):669–682. https://doi.org/10.1093/neuonc/noab269
Yang W, Yuan Q, Zhang S, Zuo M, Li T, Li J, Zhou X, Li M, Feng W, Xia X, Chen M, Liu Y (2022) Elevated GIGYF2 expression suppresses tumor migration and enhances sensitivity to temozolomide in malignant glioma. Cancer Gene Ther 29(6):750–757. https://doi.org/10.1038/s41417-021-00353-1
Yuan Q, Yang W, Zhang S, Li T, Zuo M, Zhou X, Li J, Li M, Xia X, Chen M, Liu Y (2021) Inhibition of mitochondrial carrier homolog 2 (MTCH2) suppresses tumor invasion and enhances sensitivity to temozolomide in malignant glioma. Mol Med 27(1):7. https://doi.org/10.1186/s10020-020-00261-4
Zhang Z (2016) Parametric regression model for survival data: Weibull regression model as an example. Ann Transl Med 4(24):484. https://doi.org/10.21037/atm.2016.08.45
Zhu J, Cai Y, Liu P, Zhao W (2016) Frequent Nek1 overexpression in human gliomas. Biochem Biophys Res Commun 476(4):522–527. https://doi.org/10.1016/j.bbrc.2016.05.156
Acknowledgements
All the authors sincerely thank Dr. Hao Xu for the technical help on statistical analysis.
Funding
This research was supported by Sichuan Science and Technology Program (no. 2023YFSY0042).
Author information
Authors and Affiliations
Contributions
Conceptualization: XQ, MC, WY; data collections: XQ, QY, XX, WL; data analysis: XQ, QY, WY; manuscript writing: MC, WY. All the authors approved the submission.
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Ethics approval and consent to participate
No ethics approval should be declared.
Consent for publication
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Qi, X., Yuan, Q., Xia, X. et al. Clinical and molecular analysis of cilia-associated gene signature for prognostic prediction in glioma. J Cancer Res Clin Oncol 149, 11443–11455 (2023). https://doi.org/10.1007/s00432-023-05022-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-023-05022-4